Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials H1 2021 free cash flow growing to USD 5.8bn Group free cash flow¹ USD bn, % USD 5.7 +3% + 5.8 H1 2020 H1 2021 Key drivers vs. PY: - Higher divestment proceeds Tislelizumab in-licensing (upfront payment USD 650m) 1. Free cash flow is a non-IFRS measure. An explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report. 44 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation